Précisez une action ou une cryptomonnaie dans la barre de recherche pour obtenir un récapitulatif
Genflow Biosciences plc
GENFFGenflow Biosciences plc, together with its subsidiaries, operates as a biotechnology company that focuses on developing biological interventions aimed at tackling the effects of ageing, slowing, and halting the ageing process, and reducing the incidence of age-related diseases with increase in health span in the United Kingdom and Belgium. Its lead compound is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-3001, a topical delivery of SIRT6 to the skin; and GF-4001, a non-human pipeline anti-aging for veterinary use. Genflow Biosciences plc was incorporated in 2021 and is headquartered in London, the United Kingdom. Address: 6 Heddon Street, London, United Kingdom, W1B 4BT
Analytics
Objectif de Cours de WallStreet
–Ratio C/B
–Rendement du dividende
–Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Chiffres clés GENFF
Analyse des dividendes GENFF
Croissance des dividendes sur 5 ans
–Croissance continue
–Ratio de distribution Moyenne sur 5 ans
–Historique des dividendes GENFF
Valorisation des titres GENFF
financières GENFF
Résultats | 2019 | Dynamique |